Liraglutide: a human GLP-1 analog for Type 2 diabetes

ISSN： 1475-0708

Source： Therapy, Vol.6, Iss.2, 2009-03, pp. : 199-207

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dulaglutide: a once‐weekly GLP‐1 for type 2 diabetes

PRESCRIBER, Vol. 26, Iss. 19, 2015-10 ,pp. : 28-30

John Wiley & Sons Inc

Access to resources Recommend Favorite

Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes

By Ross Stuart A. Ballantine Jane

Current Medical Research and Opinion, Vol. 29, Iss. 12, 2013-12 ,pp. : 1617-1626

Informa Healthcare

Access to resources Recommend Favorite

Current treatments and strategies for type 2 diabetes: Can we do better with GLP-1 receptor agonists?

By Peterson Gregory

Annals of Medicine, Vol. 44, Iss. 4, 2012-06 ,pp. : 338-349

Informa Healthcare

Access to resources Recommend Favorite

Lixisenatide, a novel GLP‐1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 16, Iss. 7, 2014-07 ,pp. : 588-601

John Wiley & Sons Inc

Access to resources Recommend Favorite

GLP-1 receptor agonists and HBA_1c target of <7%% in type 2 diabetes: meta-analysis of randomized controlled trials

By Esposito K. Mosca C. Brancario C. Chiodini P. Ceriello A. Giugliano D.

Current Medical Research and Opinion, Vol. 27, Iss. 8, 2011-08 ,pp. : 1519-1528

Informa Healthcare

Access to resources Recommend Favorite